Discusses Roluperidone as a Potential First Treatment for Negative Symptoms of Schizophrenia February 3, 2026 10:30 ...

A new study suggests that the long-term antidepressant effects of psychedelics may be driven by persistent changes in how ...

The cash injection will also allow Corxel to start phase 2 testing in type 2 diabetes and help to fund a phase 3 programme in ...

Laboratory tests of a novel serotonin-binding compound have revealed an unexpected disconnect between receptor activation and behavior, raising new questions about how psychedelic effects emerge in ...

This article and associated images are based on a poster originally authored by Sophie O’Neil, Kyle Thompson, Rita Pereira, Emily Russell and Stuart McElroy and presented at ELRIG Drug Discovery 2025 ...

This article and associated images are based on a poster originally authored by Elisabetta Perdona, Palmina Cavallini, Alessia Auber, Mattia Musto, Martina Antolini, Stefania Faedo, Giovanni Benedetti ...

5-year UG3/UH3 grant will fund the optimization and early-stage development of atai’s novel 5-HT2A/2C receptor agonists with non-hallucinogenic potential for opioid use disorder NEW YORK and AMSTERDAM ...

1 Department of Geriatrics, The First Hospital of China Medical University, Shenyang, Liaoning, China 2 Department of Psychiatry, Shengjing Hospital of China Medical University, Shenyang, Liaoning, ...

Provided herein are novel compounds as 5-HT2A agonists, pharmaceutical compositions, use of such compounds in treating depression, and processes for preparing such compounds. Depression was for a long ...

Summary: Classical psychedelics like LSD, psilocybin, and mescaline are known for activating the 5-HT2A serotonin receptor, but a new study reveals their effects go far beyond. Researchers profiled 41 ...

Introduction: Many Veterans who experienced blast-related traumatic brain injuries (TBIs) in Iraq and Afghanistan currently suffer from chronic cognitive and mental health problems that include ...

GM-2505, a novel 5-HT2A receptor agonist and 5-HT releaser, demonstrated rapid, robust, and durable antidepressant effect in MDD NEW YORK, May 27, 2025 /PRNewswire/ -- Gilgamesh Pharmaceuticals, a ...